Pharma Journalist -

Sierra Oncology which is a clinical stage drug development company aiming to further the DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today…
Read More...

Celltex Therapeutics Corporation asserted its authorization to conduct an investigational protocol which is a Phase II B Wellness Protocol Clinical Study on Rheumatoid Arthritis and…
Read More...

Aldeyra Therapeutics enters into a collaborative research agreement with Janssen Research and Development, LLC which is ideally one of the Janssen Pharmaceutical Companies of Johnson…
Read More...

Aridis Pharmaceuticals applying proprietary technologies to curate novel anti-infectives and immunotherapies for infectious diseases proclaimed that it has created a Joint Venture with …
Read More...

Beacon Discovery asserted the formulation of a multi-year drug discovery collaboration with Takeda Pharmaceutical Company aiming to develop G-protein coupled receptors paving way for…
Read More...

Amgen asserted that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending a label variation for Neulasta…
Read More...

Abbott and Surmodics proclaimed having forayed into an agreement wherein Abbott will possess exclusive commercialization rights for Surmodic's Surveil drug-coated balloon to treat the…
Read More...

Longeveron asserted that its revolutionary Clinical Trial initiated to treat infants with Hypoplastic Left Heart Syndrome as the first patient received the treatment using the company's…
Read More...

Medical device company reinventing venous access using proprietary material technology designed to reduce thrombus accumulation, Access Vascular asserted that the Company has sought …
Read More...

Eli Lilly and Company proclaimed that the USFood and Drug Administration has sanctioned Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based…
Read More...